Recombinant human activated protein c (rhapc) or drotrecogin alfa (activated)

P and T

Volumn 27, Issue 4, 2002, Pages 190-194

  Leady, Michelle ^a   Kraft, Michael ^a   Alaniz, Cesar ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DROTRECOGIN; INTERLEUKIN 1; INTERLEUKIN 6; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANTIINFLAMMATORY ACTIVITY; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SHORT SURVEY; TREATMENT OUTCOME;

EID: 0036223729     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (8)

1. Low levels of protein c are associated with a poor outcome in severe sepsis
2. Severe sepsis- a new treatment with both anticoagulant and anti-inflammatory properties
3. Treating patients with severe sepsis
4. Efficacy and safety of recombinant human activated protein c for severe sepsis
5. Safety and dose relationship of recombinant human activated protein c for coagulopathy in severe sepsis
6. Changes in markers of coagulation and inflammation in patients with severe sepsis treated with recombinant human activated proteinc